Jubilant Biosys completes acquisition of Pierre Fabre's R&D centre

Jubilant Pharmova Limited (BSE: JUBLPHARMA) announced today that its subsidiary, Jubilant Biosys Innovative Research Services Pte Limited (JBIRSPL), Singapore, has completed the acquisition of Pierre Fabre SA's (PF) R&D Centre in Saint Julien, France. JBIRSPL subscribed to 80% equity capital in JASMIN, a French company incorporated by PF, with PF retaining the remaining 20%. Concurrently with the equity subscription, JASMIN acquired PF's R&D Centre. Following the transaction, the name of JASMIN has been changed to 'Jubilant Biosys France', now a subsidiary of JBIRSPL. This strategic acquisition marks a significant expansion of Jubilant Biosys' research and development capabilities. The information was disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The event occurred on March 19, 2025, at 11:54 pm (IST).